Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: The Company develops noninvasive diagnostics for early-stage lung cancer (CyPath® Lung) using flow cytometry and AI. It operates through its subsidiary, Precision Pathology Laboratory Services, LLC (PPLS), and conducts R&D for therapeutic candidates targeting cancer receptors.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Net Revenue | $3,123,080 | $4,804,043 |
| Net Loss | $(6,721,204) | $(4,072,094) |
| Net Loss Per Share (Basic/Diluted) | $(0.20) | $(0.38) |
| Cash and Cash Equivalents (End of Period) | $802,835 | $801,311 |
| Accumulated Deficit | $(60,365,514) | $(48,676,573) |
| Warrant Liability | $3,974,911 | $0 |
| Working Capital Deficit | $(919,478) | $(409,807) |
Note: Working Capital calculated as Total Current Assets ($1,668,826) minus Total Current Liabilities ($2,588,304).
Material Changes vs. Prior Period
- Revenue Decline: Consolidated revenue decreased 35% to $3.1 million. This was driven by the strategic discontinuation of unprofitable pathology services. However, revenue specifically from the CyPath® Lung test increased approximately 62% (from $199,000 to $323,000) due to higher test volume.
- Increased Net Loss: Net loss widened to $6.7 million from $4.1 million. The primary driver was a $1.06 million non-cash loss from the remeasurement of warrant liabilities associated with the May 2025 public offering.
- Operating Expenses: Total operating expenses decreased 6% to $8.3 million. Direct costs and R&D expenses declined due to cost-cutting measures, while clinical development expenses increased 167% due to professional fees for pivotal trial strategy.
- Capital Structure: The Company completed a public offering in May 2025 raising $3.25 million in gross proceeds. This resulted in a significant increase in outstanding warrants and the recognition of a new warrant liability.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for at least 12 months. Despite recent financing, cash resources are projected to be insufficient to fund operations beyond August/September 2025 without additional capital.
- Outlook: The Company reaffirmed a forecast of 3x year-over-year revenue growth for CyPath® Lung. Recent case studies and record monthly sales in June and July 2025 support this trajectory.
- Nasdaq Compliance: The Company received notice of non-compliance with Nasdaq listing rules regarding minimum bid price (below $1.00) and minimum stockholders' equity (below $2.5 million). An appeal hearing was requested in August 2025 to stay delisting actions.
- Financing Needs: The Company must raise further capital through equity, debt, or strategic relationships to continue operations and development. Failure to do so may result in curtailment of operations.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of cash reserves ($0.8M at quarter-end) against the stated burn rate and the timeline for the next capital raise.
- Warrant Liability Impact: Assess the volatility of the $4.0M warrant liability and its potential to inflate future net losses without impacting cash flow.
- Nasdaq Status: Monitor the outcome of the Nasdaq appeal hearing and the Company's plan to regain compliance with bid price and equity requirements.
- CyPath® Lung Adoption: Validate the sustainability of the 62% revenue growth in the core diagnostic test amidst the broader revenue decline from discontinued services.
- Subsequent Events: Review the August 2025 private placement of Series B Convertible Preferred Stock and warrant inducement agreements for dilution implications.